PMID- 28511371
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 2249-782X (Print)
IS  - 0973-709X (Electronic)
IS  - 0973-709X (Linking)
VI  - 11
IP  - 3
DP  - 2017 Mar
TI  - Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.
PG  - BC13-BC16
LID - 10.7860/JCDR/2017/22111.9543 [doi]
AB  - INTRODUCTION: Breast Cancer (BC) cases are rising alarmingly all over the world 
      and India is not an exception. This rising trend is due to an increased age at 
      first child birth, decreased breast feeding, and the changing lifestyle mostly in 
      urban India. With the advent of more sensitive methodologies and research works 
      in this field, it has been suggested that Prostate Specific Antigen (PSA) plays 
      an important role in the pathogenesis of breast cancer besides other established 
      tumour markers. AIM: To study the molecular forms of PSA-total and free PSA in 
      benign and malignant tumours and to analyse their association with the tumour 
      burden. MATERIALS AND METHODS: The present study was conducted in collaboration 
      with Gauhati Medical College and Hospital and Dr B Borooah Cancer Institute, 
      Guwahati, Assam, India. Women in the age group of 18-65 years with recently 
      diagnosed tumour (benign/malignant) in the breast were included in the study. 
      Women taking Oral Contraceptive Pill (OCP), hormone replacement therapy, with 
      past/present history of gynaecological/other malignancy and chronic endocrine 
      disease like diabetes, thyroid disorders were excluded. The case group comprised 
      of 50 female subjects with newly diagnosed Benign Breast Disease (BBD) and 50 
      subjects with BC, while 50 age matched healthy females without any signs and 
      symptoms of breast discomfort were included in the control group. Laboratory 
      tests done were Serum Total PSA (TPSA), Free PSA (FPSA), Fasting Blood Glucose 
      (FBS), serum urea, serum creatinine and fasting lipid profile. TPSA and FPSA was 
      measured again in both the test groups after 10-14 days of surgery/therapy. 
      RESULTS: A fall in postoperative value of total and free PSA in BC case group was 
      noticed. In Grade I tumours the mean value of total PSA (1.813 ng/ml) and free 
      PSA (1.149 ng/ml) were higher than those with Grade III tumours (TPSA-1.07 ng/ml 
      and FPSA-1.002 ng/ml). Mean value of Fasting Blood Sugar (FBG), total cholesterol 
      and Low Density Lipoprotein (LDL) in BC case group was higher than the control 
      group. CONCLUSION: From the study, we can conclude PSA as a possible new marker 
      for diagnosis and prognosis of BC.
FAU - Jahir, Elteza Tahjiba
AU  - Jahir ET
AD  - Demonstrator, Department of Biochemistry, Gauhati Medical College and Hospital, 
      Guwahati, Assam, India.
FAU - Devi, Runi
AU  - Devi R
AD  - Professor and Head, Department of Biochemistry, Gauhati Medical College and 
      Hospital, Guwahati, Assam, India.
FAU - Borthakur, Bibhuti Bhushan
AU  - Borthakur BB
AD  - Medical Superintendent, Department of Surgical Oncology, Dr. B. Borooah Cancer 
      Institute, Guwahati, Assam, India.
LA  - eng
PT  - Journal Article
DEP - 20170301
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC5427297
OTO - NOTNLM
OT  - Benign breast disease
OT  - Breast cancer
OT  - Prostate specific antigen
EDAT- 2017/05/18 06:00
MHDA- 2017/05/18 06:01
PMCR- 2017/03/01
CRDT- 2017/05/18 06:00
PHST- 2016/06/23 00:00 [received]
PHST- 2016/11/29 00:00 [accepted]
PHST- 2017/05/18 06:00 [entrez]
PHST- 2017/05/18 06:00 [pubmed]
PHST- 2017/05/18 06:01 [medline]
PHST- 2017/03/01 00:00 [pmc-release]
AID - 10.7860/JCDR/2017/22111.9543 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2017 Mar;11(3):BC13-BC16. doi: 10.7860/JCDR/2017/22111.9543. 
      Epub 2017 Mar 1.